The original success of the copyright undeniably reshaped the medication landscape, but betting in companies strongly reliant on unbranded versions presents a complex picture. Although early earnings were impressive, the end of patents and the emergence of less expensive alternatives have diminished the customer base. Consequently, a thorough asses